Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study

Ceritinib is a selective anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with unresectable advanced and/or recurrent ALK fusion gene-positive non-small cell lung cancer (NSCLC). As per the approval condition in Japan, this post-marketing surveillance (PMS) study eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneda, Hiroyasu, Kizaki, Minako, Ochi, Masami, Shiraiwa, Naoko, Akatsu, Shigemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544686/
https://www.ncbi.nlm.nih.gov/pubmed/33033286
http://dx.doi.org/10.1038/s41598-020-72863-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544686/
https://www.ncbi.nlm.nih.gov/pubmed/33033286
http://dx.doi.org/10.1038/s41598-020-72863-1

Ejemplares similares